Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Illinois researchers, including some working on vaccines for cancer and rare diseases, worry the federal government turning ...

With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement - ...

Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

Under Robert F. Kennedy Jr., federal officials may withdraw an endorsement for the vaccine in younger children.

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million ...

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna’s EP’949 patent. This decision affirms the ...

If Canada is serious about becoming a global powerhouse in fields such as AI and life sciences then this intrapreneur mindset ...